David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.
- December 07, 2022Source: SABCS Meeting News
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.
- October 04, 2022
Newly published research from Yale Pathology substantiates the impact of the drug aducanumab in reducing a plaque that is a defining pathologic feature of Alzheimer’s disease.
- August 22, 2022
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
- July 22, 2022
An objective assessment of automated electronic tumor infiltrating lymphocytes percentage (eTILs%) scores is a strong prognostic marker in patients with early-stage melanoma. The study also identifies distinct TIL subpopulations that carry the prognostic values.
- June 06, 2022
ASCO: HER2 Diagnostics Need a Revolution as AstraZeneca, Daiichi’s Enhertu Looks to Redefine Breast CancerSource: Fierce Biotech
With AstraZeneca and Daiichi Sankyo’s practice-changing clinical data for Enhertu in a new breast cancer category called HER2-low, experts have raised the necessity of revolutionizing the HER2 biomarker should be measured by diagnostic tests.
- May 11, 2022
The Accreditation Council for Graduate Medical Education (ACGME) recently awarded continued accreditation to the Neuropathy Fellowship in the Pathology Department at Yale School of Medicine.
- April 15, 2022Source: Healio
The use of current standard HER2 assays as diagnostic tests may result in misassignment of patients for treatment of breast cancer with trastuzumab deruxtecan, according to a study published in JAMA Oncology.
- March 18, 2022
Pathologists and research scientists from Department of Pathology at Yale School of Medicine will be involved in more than 40 presentations and sessions at the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting in Los Angeles March 19-24.
- February 10, 2022Source: Medscape
Standard assays for ERBB2 like the one being used in trials of trastuzumab deruxtecan (T-DXd) for breast cancer could lead to misassignment of patients with few or no copies of the protein, according to researchers who include David Rimm, MD, PhD, of Yale Pathology.